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Abstract Cytokines and chemokines are produced and secreted by a broad range of immune
cells including macrophages. Remarkably, little is known about how these inflammatory mediators
are released from the various immune cells. Here, the endolysosomal cation channel TRPML2 is
shown to play a direct role in chemokine trafficking and secretion from murine macrophages. To
demonstrate acute and direct involvement of TRPML2 in these processes, the first isoform-selective
TRPML2 channel agonist was generated, ML2-SA1. ML2-SA1 was not only found to directly
stimulate release of the chemokine CCL2 from macrophages but also to stimulate macrophage
migration, thus mimicking CCL2 function. Endogenous TRPML2 is expressed in early/recycling
endosomes as demonstrated by endolysosomal patch-clamp experimentation and ML2-SA1
promotes trafficking through early/recycling endosomes, suggesting CCL2 being transported and
secreted via this pathway. These data provide a direct link between TRPML2 activation, CCL2
release and stimulation of macrophage migration in the innate immune response.
DOI: https://doi.org/10.7554/eLife.39720.001
Introduction
Cytokines/chemokines are released from a wide range of immune cells such as macrophages, B- and
T-lymphocytes, neutrophils, mast cells and dendritic cells. They are essential for intercellular commu-
nication in both innate and adaptive immunity. Remarkably, our knowledge of the function of cyto-
kines/chemokines in immunity is much more advanced than our knowledge about how they are
packaged and secreted from immune cells. Understanding how innate immune cells release cyto-
kines/chemokines is important, as these factors are indispensable for communication between
immune but also with non-immune cells to coordinate inflammatory responses (Lacy and Stow,
2011). Importantly, secretion pathways vary between different cell types. Macrophages for example
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lack typical secretory granules (Lacy and Stow, 2011). Thus, macrophage cytokine/chemokine
release is mediated either by direct transport to the cell surface from the trans-Golgi network (TGN)
(e.g. IL-10), by transport via recycling endosomes (RE) to the cell surface (e.g. TNF-a, IL-6, IL-10)
(Manderson et al., 2007; Murray and Stow, 2014), or via late endosomes/lysosomes (LE/LY),
for example IL-1b (Andrei et al., 1999; Lopez-Castejon and Brough, 2011).
We show here that the endolysosomal calcium-permeable cation channel TRPML2 plays a direct
role in chemokine secretion, thereby modulating the inflammatory response. Expression of TRPML2
in different immune cells and tissues has been demonstrated by several groups (Cuajungco et al.,
2016; Valadez and Cuajungco, 2015; Garcı´a-An˜overos and Wiwatpanit, 2014; Sun et al., 2015).
On the subcellular level, TRPML2 has been shown to be expressed primarily on RE and LE/LY by
immunocytochemistry experiments (Sun et al., 2015; Venkatachalam et al., 2006;
Karacsonyi et al., 2007). However, functional expression of TRPML2 in different intracellular vesicles
and organelles has not been confirmed yet by direct and selective patch-clamp analysis, that is
patch-clamping of RE, EE (early endosomes), LE/LY, or other endolysosomal vesicles. Furthermore, it
remains unclear whether direct and selective stimulation of TRPML2 leads to an increase in cytokine/
chemokine release from macrophages, and which intracellular trafficking pathways mediate the
release of these cytokines/chemokines.
One important impediment for the investigation of different endogenous TRPML-like currents
and their functional impact on secretion, endolysosomal trafficking, or autophagy, is the lack of iso-
form-selective agonists. Development of such agonists would allow demonstration of the TRPML iso-
form-specific contribution towards observed phenomena, for example chemokine secretion.
Currently available TRPML channel agonists belong to different chemotypes, including benzenesulfo-
namides (e.g. SN-1- or SF-21-type), thiophenesulfonamides (e.g. SF-22-type, including MK6-83), iso-
indolediones (e.g. SF-51-type, including ML-SA1), isoxazolines (e.g. SN-2-type) and others
(Grimm et al., 2010; Yamaguchi and Muallem, 2010; Grimm et al., 2012b; Shen et al., 2012). Effi-
cacy, potency and selectivity of these compounds can vary between species. Furthermore, none of
the currently available TRPML agonists is selective for TRPML1 or TRPML2. ML-SA1 for example acti-
vates TRPML1 and TRPML3 in mouse, while it activates all three human isoforms (Shen et al., 2012;
Grimm, 2016). MK6-83 activates TRPML1 and TRPML3 in both mouse and human (Grimm, 2016;
Chen et al., 2014). The putative endogenous TRPML channel activator PI(3,5)P2 activates all three
TRPML channel isoforms in both species and, in addition, also activates the endolysosomal cation
channels TPC1 and TPC2 (Chen et al., 2014; Wang et al., 2012; Cang et al., 2013; Grimm et al.,
2014). Through systematic chemical modification of known lead structures we have now generated
the first isoform-selective TRPML2 channel agonist, ML2-SA1.
We demonstrate that ML2-SA1 activates TRPML2 in EE and LE/LY as well as in Rab11+ and Tf+/
TfR+ (transferrin/transferrin receptor) vesicles. In macrophages, LPS (lipopolysaccharide) exposure
leads to a strong upregulation of TRPML2 expression, while TRPML1 and TRPML3 expression levels
remain unaffected by LPS (Sun et al., 2015). Importantly, activation by ML2-SA1 was not observed
in macrophages without LPS treatment which express TRPML2 only at very low levels, further con-
firming specificity of the compound. We also show that direct activation of TRPML2 by ML2-SA1
results in an increased release of the chemokine CCL2 from LPS-stimulated WT macrophages, while
TRPML2-/- macrophages show no release increase, suggesting that TRPML2 channel activity is
directly linked to CCL2 trafficking and secretion. We further provide evidence that CCL2 is released
via the early/recycling endosomal pathway but not via LE/LY. Finally, we show that stimulation with
ML2-SA1 promotes macrophage migration, one of the major physiological functions of the chemoat-
tractant CCL2, one synonym of which is monocyte chemoattractant protein 1 (MCP-1).
Results
Development of a potent isoform-selective TRPML2 channel agonist
With the aim to further improve the characteristics of existing TRPML channel agonists, we gener-
ated more than 80 novel derivatives of recently reported lead activators of TRPML channels which
had been originally identified by random screening of the MLSMR small molecule library (Scripps
Research Institute Molecular Screening Center) (Grimm et al., 2010). Here, novel derivatives of the
lead compounds SN-2 and ML-SA1, a SF-51 analogue (Grimm et al., 2010; Shen et al., 2012;
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Grimm, 2016; Chen et al., 2014) were evaluated for their efficacy, potency, and selectivity profiles,
respectively.
We first synthesized and tested >50 chemically modified versions of the TRPML3 activator SN-2
(Figure 1; Figure 1—figure supplement 1; Supplementary file 1). These modifications comprise
systematic variations of the substitution pattern of the aryl ring, variations of the aliphatic norbor-
nane ring system, aromatisation of the isoxazoline to an isoxazole fragment, introduction of polar
substituents, as well as replacement of the isoxazol(in)e ring by other heterocycles. Crucial steps in
these syntheses were Huisgen-type 1,3-dipolar cycloaddition reactions of norbornene (for the closer
analogues) and other alkenes with nitrile oxides (Jawalekar et al., 2011; Huisgen, 1963) and related
1,3-dipoles. Related aromatic isoxazole analogues were prepared via cycloaddition of nitrile oxides
with ketone enolates (Vitale and Scilimati, 2013) or enamines (Fos et al., 1992). General synthesis
strategies for these modifications are shown in Figure 1A.
Derivatives of SF-51/ML-SA1 (Figure 1—figure supplement 2; Figure 1—figure supplement 3;
Supplementary file 1) were synthesized by combining appropriate amine building blocks (partially
hydrogenated quinolines and other cyclic and open-chain analogues) with N-acyl spacers and imide/
lactam-type residues following standard procedures (Figure 1—figure supplement 3A).
Following synthesis, we initially tested the compounds in HEK293 cells transiently transfected
with human TRPML1, TRPML2, or TRPML3 (C-terminally fused to YFP) by using the fura-2 calcium
imaging technique. When expressed in HEK293 cells, TRPML2 and TRPML3 but not TRPML1 sub-
stantially localize at the plasma membrane besides endolysosomes as described previously
(Grimm et al., 2010), enabling standard fura-2 calcium imaging experimentation. To evaluate effects
on TRPML1, a plasma membrane variant with mutated lysosomal targeting sequences in the N- and
C-termini (TRPML1(NC)) was used as reported previously (Grimm et al., 2010).
The majority of the SN-2 and SF-51/ML-SA1 derivatives were either inactive, non-selective like
ML-SA1, or selective for TRPML3 like SN-2 (Figure 1B; Figure 1—figure supplement 3B). A subset
of molecules however displayed a strong preference for TRPML2: ML2-SA1 (=EVP-22), a derivative
of SN-2, as well as derivatives of SF-51/ML-SA1: EVP-198, EVP-207 and EVP-209. The latter three
SF-51/ML-SA1 derivatives however showed lower efficacy compared to ML2-SA1 (Figure 1B; Fig-
ure 1—figure supplement 3B).
TRPML2 activity is detectable in EE, LE/LY as well as Rab11+ and TfR
+ organelles
In endolysosomal patch-clamp experiments using transiently transfected HEK293 cells, we investi-
gated TRPML2 channel activity in wortmannin/latrunculin B (Wort./Lat.B)-enlarged EE (Chen et al.,
2017a), in YM201636-enlarged LE/LY (Chen et al., 2017a), as well as in vacuolin-enlarged Rab11
+ and TfR+ organelles (Figure 2; Figure 2—figure supplement 1). In LE/LY, both ML2-SA1
(Figure 2B; Figure 2—figure supplement 1A) and PI(3,5)P2 (Figure 2—figure supplement 1A)
evoked TRPML2 activation while no or very little activation was detectable for TRPML1 and TRPML3.
In contrast, the latter ones were robustly activated by ML-SA1 as a positive control (Figure 2C–E).
The time course for activation of TRPML2 in LE/LY patch-clamp experiments and the relative Ca2+
permeability are shown in Figure 2G and Figure 2—figure supplement 1B. In addition to LE/LY,
TRPML2 channel activity was also detectable in EE after stimulation with ML2-SA1 (Figure 2H and
K). In order to patch-clamp discrete populations of vesicles involved in early/recycling endosomal
trafficking, cells were transfected with fluorophore-tagged Rab11 or TfR, and enlarged with vacuolin.
ML2-SA1 elicited significant currents in Rab11+ and in TfR+ vesicles (Figure 2I–K).
Furthermore, the effect of luminal pH on TRPML2 channel activity was evaluated (Figure 2—fig-
ure supplement 1A and C). TRPML2 activity (stimulated with PI(3,5)P2 or with ML2-SA1) increases
with increasing, that is less acidic luminal pH. This differs from TRPML1 which shows maximal activity
in highly acidic luminal pH (Chen et al., 2017a; Dong et al., 2010). These findings argue TRPML2
channel function is adapted to vesicles of only slightly acidic or neutral pH such as EE/RE rather than
highly acidic LE/LY. The strong colocalization between TfR or Rab11 with TRPML2 confirms an
important functional role of TRPML2 in RE (Figure 2—figure supplement 2A–B).
In summary, ML2-SA1 was found to be a potent and efficacious activator of both hTRPML2 and
mTRPML2. The calculated EC50 values for human and mouse TRPML2 were 1.24 ± 0.12 mM and
2.38 ± 0.01 mM, respectively (Figure 2F; Figure 2—figure supplement 3A). ML2-SA1 shows high
selectivity over h/mTRPML1 and h/mTRPML3 in both calcium imaging and endolysosomal patch-
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Figure 1. Chemical synthesis strategies and functional evaluation of SN-2 analogous compounds using calcium imaging. (A) Shown are synthesis
strategies a and b used to generate most of the SN-2 analogous compounds shown in Suppl. Figure 1. R1 = alkyl/ halogen/nitro/ methoxy; R2 / R3 =
(cyclo)alkyl/phenyl/ hydroxyalkyl; R4 / R5=alkyl/ phenyl / (hetero)cycles; a) H2N-OH . HCl (1.5 eq.), NaOH (3 eq.), H2O:EtOH (1:1), 0˚C - rt, 18 hr; b) PIFA
(1.2 eq.), alkene (1.5 eq.), H2O:MeOH (1:2), rt, 1–24 hr; c) ketone (2 eq.), LDA (2 eq.), THF,  78˚C, 2 hr, mesitonitrile oxide,  78˚C - rt, 2–15 hr; d)
Figure 1 continued on next page
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clamp experiments and it does not activate TPC1 nor TPC2 (Figure 1; Figure 2; Figure 2—figure
supplement 3B–F).
Molecular modeling of ML2-SA1 binding
Several recent papers have provided in-depth information on the structures of TRPML1 and TRPML3
channels (Schmiege et al., 2017; Chen et al., 2017b; Hirschi et al., 2017). Schmiege et al., 2017
found that a hydrophobic cavity created by I468 and F465 of PH1 (pore helix 1), F428, C429, V432
and Y436 of S5, F505 and F513 of S6, and Y499 and Y507 of S6 in the neighboring subunit, tightly
accommodates ML-SA1 (Figure 3A). In a molecular modeling approach using these recently pub-
lished structures of TRPML1 and TRPML3 as a basis, we simulated the binding of ML-SA1 as well as
ML2-SA1 to hTRPML1 and hTRPML2 (Figure 3; Figure 3—figure supplement 1). Complete 3D
models of the open conformation of hTRPML1 and hTRPML2 were constructed and used for ligand
docking analysis. Amino acids differing between hTRPML1 and hTRPML2 are colored green
(Figure 3B–D). Based on this model, ML2-SA1 (both enantiomers are described, one in Figure 3—
figure supplement 1) is predicted to bind to the same binding pocket as ML-SA1 as observed in
the cryo-EM structure of hTRPML1 (Figure 3A–B). Six amino acids (A422, A424, G425, A453, V460,
and I498) in this pocket are unique to hTRPML2 (highlighted in green; Figure 3C–D). The orientation
of ML2-SA1 in the binding pocket of hTRPML2 with the highest docking score is shown in
Figure 3C. The dichlorophenyl ring shows favorable p-stacking interaction with F502 whereas the
polar isoxazole ring is located near the side chain OH-groups of Y428 and Y496. The hydrophobic
norbornane ring is interacting with G425 and Y428. Other possible orientations of ML2-SA1 binding
to hTRPML2 are shown in Figure 3—figure supplement 1C–D). The observed binding mode of
ML2-SA1 at hTRPML1 is different and appears to be energetically less favorable compared to
hTRPML2 due to the observed amino acid substitutions in the predicted binding cavity (Figure 3D).
We subsequently replaced each of the six amino acids that are unique to the predicted hTRPML2
binding pocket with the respective amino acids of hTRPML1. We analysed these mutant isoforms
first in calcium imaging experiments where we found the strongest reduction of the ML2-SA1 effect
in G425A (Figure 3E). In the next step, we performed endolysosomal patch-clamp experiments with
this mutant. Mutation of G425 to alanine was found to selectively abrogate the effect of ML2-SA1,
while ML-SA1 was still able to activate G425A to a degree not significantly different from WT
(Figure 3E–F). G425 is close to the norbornane ring of ML2-SA1 (minimum distance 3.6 A˚) docked
to hTRPML2 and substitution to alanine is unfavorable for this binding mode (Figure 3C). The exper-
imental data corroborate binding of ML2-SA1 to the ML-SA1 binding pocket and confirm a critical
role of G425 in mediating ML2-SA1 selectivity.
Effect of ML2-SA1 on endogenous TRPML2 channel activity in
organelles isolated from LPS-stimulated macrophages
In macrophages significant TRPML2 channel expression is found only after stimulation with LPS, as
demonstrated previously by qRT-PCR and western blot analysis (Sun et al., 2015). We confirmed
this finding by qRT-PCR and endolysosomal patch-clamping, revealing that only after several hours
of LPS treatment, robust endogenous TRPML2 channel expression and activity were detectable
Figure 1 continued
Na2CO3, MeOH:H2O (2:1), 95˚C, 2 hr. (B) Cartoon showing schematically the fractions of inactive, non-selective TRPML activating, TRPML2-selective,
and TRPML3-selective agonists (total number = 55). (C) Fura-2 calcium imaging results showing the effect of SN-2 and its analogues (10 mM) on
hTRPML1(NC)-YFP, hTRPML2-YFP, and hTRPML3-YFP transfected HEK293 cells. Mean values normalized to basal (200 s after compound application)±
SEM of up to >100 independent experiments with 3–10 cells per experiment are shown.
DOI: https://doi.org/10.7554/eLife.39720.002
The following figure supplements are available for figure 1:
Figure supplement 1. Structures of SN-2 analogues.
DOI: https://doi.org/10.7554/eLife.39720.003
Figure supplement 2. Structures of SF-51/ML-SA1 analogues.
DOI: https://doi.org/10.7554/eLife.39720.004
Figure supplement 3. Chemical synthesis strategies and functional evaluation of SF-51/ML-SA1-analogous compounds using calcium imaging.
DOI: https://doi.org/10.7554/eLife.39720.005
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Figure 2. Effect of ML2-SA1 on TRPML channels. (A) Cartoon depicting chemical structures of SN-2 and ML2-SA1. (B) Representative ML2-SA1 or ML-
SA1 (10 mM) elicited currents from YM201636-enlarged LE/LY isolated from hTRPML2 expressing HEK293 cells. (C–D) Representative ML2-SA1 or ML-
SA1 (10 mM) elicited currents from YM201636-enlarged LE/LY isolated from hTRPML1 or hTRPML3 expressing HEK293 cells. (E) Statistical summary of
ML2-SA1 data as shown in B-D as fold increase compared to the respective basal currents in LE/LY. Shown are mean values ± SEM at  100 mV of n
Figure 2 continued on next page
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(Figure 4A–G). In LPS-stimulated bone marrow-derived macrophages (BMDMF) ML2-SA1-induced
currents were detectable in Tf-Alexa555 loaded, vacuolin-enlarged vesicles, while no significant
TRPML2 channel activity could be detected in non-LPS stimulated BMDMF Tf+ vesicles (Figure 4A–
B). Currents measured in BMDMF LE/LY with ML2-SA1 after LPS-stimulation were smaller than cur-
rents measured in Tf+ loaded vesicles (Figure 4C–D). In contrast, in LE/LY isolated from alveolar
macrophages (AMF), TRPML2 currents elicited with ML2-SA1 were larger on average than in
BMDMF (Figure 4E–F). These data confirm that ML2-SA1 elicits robust TRPML2 currents in endoge-
nously expressing cells.
Effect of selective TRPML2 activation on CCL2 secretion
To evaluate effects of the novel TRPML2 channel agonist on chemokine secretion from macro-
phages, we performed experiments based on the results recently provided by Sun et al. (2015)
(Figure 5A). We found that incubation with ML2-SA1 significantly increased secretion of the chemo-
kine CCL2 from BMDMF, both after 4 hr and 8 hr of LPS treatment (Figure 5A). Importantly, ML2-
SA1 did not induce CCL2 secretion in unstimulated BMDMF. Furthermore, CCL2 secretion was
severely reduced in TRPML2-/- BMDMF and ML2-SA1 showed no further increase of CCL2 secretion
in the TRPML2-/- BMDMF, corroborating the specificity of the agonist (Figure 5A). To characterise
the pathway of ML2-SA1-induced CCL2 secretion from macrophages, we performed lysosomal exo-
cytosis and Tf trafficking experiments to distinguish between LE/LY and EE/RE as possible secretion
routes. Lysosomal exocytosis experiments revealed no significant effect of ML2-SA1 on lysosomal
enzyme (beta-hexosaminidase) release (Figure 5B). In accordance with this, ML2-SA1 application did
not result in translocation of LAMP1 to the plasma membrane (Figure 5C), arguing against LE/LY
being involved in CCL2 secretion in BMDMF. These findings are supported by the LE/LY environ-
ment being less favorable for TRPML2 activity as outlined above. More favorable conditions are
found in EE/RE compartments (less acid to neutral pH). In line with this, ML2-SA1 application
resulted in a significant enhancement of Tf trafficking and recycling through EE/RE (Figure 5D–E).
Taken together, these data argue for a TRPML2-dependent trafficking route of CCL2 from Golgi to
EE/RE (Figure 5F).
ML2-SA1 promotes macrophage migration
To assess effects of ML2-SA1 on cell migration, we performed migration assays in a modified Boy-
den chamber setup (Figure 6—figure supplement 1). BMDMF in the presence or absence of LPS
were seeded in the lower compartment of the chamber and exposed to different concentrations of
ML2-SA1. LPS-stimulated, ML2-SA1 pre-treated BMDMF were able to significantly increase migra-
tion of untreated BMDMF through the transwell chamber, while LPS-stimulated BMDMF without
ML2-SA1 pre-treatment (only DMSO) were not able to alter migration properties of untreated
BMDMF. (Figure 6A). This is in accordance with the enhanced release of CCL2 by ML2-SA1, which
Figure 2 continued
independent experiments as indicated, each. (F) Dose-response curves obtained from fura-2 calcium imaging experiments with hTRPML1(NC),
hTRPML2, and hTRPML3 expressed in HEK293 cells and elicited with ML2-SA1 at varying concentrations. The calculated EC50 value for hTRPML2 is:
1.24 ± 0.12 mM (mean ± SEM). (G) Time course of TRPML2 activation by ML2-SA1 taken from experiments as shown in B. Black and red arrows indicate
time points for basal and ML2-SA1 induced TRPML2 activity that were used for the IV relationship. (H–J) Representative basal and ML2-SA1 (10 mM)
elicited currents from Wort./Lat.B-enlarged EE, from vacuolin-enlarged Rab11+, or form TfR+ vesicles isolated from hTRPML2 expressing HEK293 cells.
(K) Statistical summary of data as shown in G-I. * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, Figure 2E, one-way ANOVA test followed
by Tukey’s post-hoc test, Figure 2J, paired t-test.
DOI: https://doi.org/10.7554/eLife.39720.006
The following figure supplements are available for figure 2:
Figure supplement 1. Effect of ML2-SA1 on TRPML2 under different pH conditions.
DOI: https://doi.org/10.7554/eLife.39720.007
Figure supplement 2. Co-transfection of HEK293 cells with fluorescently labelled TRPML2 and vesicle-specific markers of the endolysosomal system.
DOI: https://doi.org/10.7554/eLife.39720.008
Figure supplement 3. DRC of ML2-SA1 effect on mTRPML2, effects of ML2-SA1, SN2, and ML-SA1 on mTRPML channel isoforms, and cytotoxicity of
ML2-SA1.
DOI: https://doi.org/10.7554/eLife.39720.009
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Figure 3. Molecular modeling of ML2-SA1 and ML-SA1 binding. (A) Binding mode of ML-SA1 (green colored carbon atoms) at hTRPML1, showing
residues within 5 A˚ of ML-SA1, as observed in one of the four identical binding pockets of the cryo-EM structure (PDB ID: 5WJ9). The S6 helix of
monomer A of hTRPML1 is colored magenta, the PH1 and S5 helices of monomer B are colored cyan. (B) Binding mode of ML-SA1 (green colored
carbon atoms) at hTRPML2 (homology model generated with MODELLER) as predicted by the ligand docking. Only residues within 5 A˚ of ML-SA1 in
Figure 3 continued on next page
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serves as chemoattractant for untreated BMDMF. To exclude a chemotactic effect of the com-
pounds themselves, we used a classical Boyden chamber setup without cells in the lower compart-
ment. Yet, neither LPS nor ML2-SA1 alone were able to significantly enhance BMDMF migration,
while supplementation of recombinant CCL2 led to a substantial increase in BMDMF migration
(Figure 6B; Figure 6—figure supplement 2A–B). Overall, these data suggest that ML2-SA1 is able
to induce CCL2 secretion selectively in TRPML2-expressing macrophages, thus serving as chemoat-
tractant to recruit more macrophages.
Discussion
We describe here a novel, isoform-selective activator of the TRPML2 channel and describe how
TRPML2 activation enhances endosomal trafficking to induce inflammatory mediator release in LPS-
stimulated macrophages. Until now, selective activators for TRPML2 had not been available. In an
effort to identify such selective activators we synthesized >80 chemical compounds by systematic
variation of the known lead structures SN-2 and SF-51/ML-SA1 (Grimm et al., 2010; Shen et al.,
2012), generating a library of analogues of sufficient size to deduce structure-activity relationships.
In the ML-SA1 series, improved TRPML2 activation was achieved by modification of the length of
the acyl spacer, but the resulting selective activators were of only intermediate efficacy and potency.
By contrast, the activator ML2-SA1 from the series of norbornene-derived isoxazolines (based on
SN-2) is characterized by high TRPML2 subtype selectivity as well as high efficacy and potency, ren-
dering this new small molecule a valuable compound for future studies on this ion channel
(Supplementary file 2). Molecular modeling data support specific binding of ML2-SA1 to the pore
region of the channel, as observed for ML-SA1. The binding orientation of ML-SA1 at hTRPML2 was
found to be similar to the experimentally observed binding to hTRPML1 (Schmiege et al., 2017)
which is in agreement with nonselective activation. In contrast, the binding orientation of docked
ML2-SA1 at hTRPML1 differs from that found for hTRPML2, suggesting a plausible rationale for its
selectivity. In an experimental approach where we investigated the functional consequences of point
mutations in hTRPML2 with the endolysosomal patch-clamp technique we found that in mutant
G425A activation by ML2-SA1 is selectively lost, while activation by ML-SA1 is preserved, indicating
that this amino acid is highly critical for the selective effect of ML2-SA1 on TRPML2.
Sun et al. (2015) have recently shown that the levels of TRPML2 are strongly upregulated in mac-
rophages upon TLR4 (toll-like receptor) activation (Supplementary file 2). Thus, treatment with LPS
was found to lead to TRPML2 upregulation in, for example microglia, peritoneal macrophages, bone
marrow derived macrophages, or alveolar macrophages (Sun et al., 2015). The authors further
found that the translation and secretion of several chemokines such as CCL2 was reduced in
TRPML2-/- mice, and concluded that TRPML2 might play a role in the regulation of trafficking and/or
Figure 3 continued
one of the four identical binding pockets are displayed. The S6 helix of monomer A of hTRPML2 is colored petrol blue, the PH1 and S5 helices of
monomer B are colored salmon. Amino acid residues that are different in hTRPML1 and hTRPML2 are colored green (C) Binding mode of one ML2-SA1
enantiomer (cyan colored carbon atoms; 3aS, 4S, 7R, 7aS) at hTRPML2 as predicted by ligand docking. Only residues within 5 A˚ of ML2-SA1 in one of
the four identical binding pockets are displayed (same coloring and representation style as in Figure 3B). Binding of the other ML2-SA1 enantiomer
(3aR, 4R, 7S, 7aR) resulted in a similar binding mode that is shown in Figure 3—figure supplement 1B (D) Binding mode of one ML2-SA1 enantiomer
(cyan colored carbon atoms; 3aS, 4S, 7R, 7aS) at hTRPML1 as predicted by ligand docking. Only residues within 5 A˚ of ML2-SA1 in one of the four
identical binding pockets are displayed (same coloring and representation style as in Figure 3a). (E) Fura-2 calcium imaging results showing the effect
of ML2-SA1 (10 mM) on hTRPML2-YFP WT and mutant transfected HEK293 cells. Mean values normalized to basal (120 s after compound application)±
SEM of at least three independent experiments, each. * indicates p<0.05, one-way ANOVA, followed by Dunnet post-hoc test. (F) Representative ML2-
SA1 or ML-SA1 (10 mM) elicited currents from YM201636-enlarged LE/LY isolated from hTRPML2(G425A) expressing HEK293 cells. (G) Statistical
summary of data as shown in F as fold increase compared to the respective basal currents in LE/LY. Shown are mean values ± SEM at  100 mV of at n
independent experiments as indicated. * indicates p<0.05, unpaired t-test.
DOI: https://doi.org/10.7554/eLife.39720.010
The following figure supplement is available for figure 3:
Figure supplement 1. Additional molecular modeling of ML2-SA1 and ML-SA1 binding.
DOI: https://doi.org/10.7554/eLife.39720.011
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Figure 4. Effect of ML2-SA1 on channel currents in endolysosomal organelles isolated from different primary mouse macrophages. (A) Representative
currents from vacuolin-enlarged/Tf+ vesicles isolated from murine (LPS 6 hr or LPS 0 hr) primary WT BMDMF, basal or elicited by an application of 10
mM ML2-SA1. All currents are normalized to basal current without ML2-SA1. (B) Statistical summary of data shown in A. (C) Representative currents from
YM201636-enlarged LE/LY isolated from murine (LPS 6 hr or LPS 0 hr) primary WT bone marrow macrophages (BMDMF), basal or elicited by an
application of 10 mM ML2-SA1. (D) Statistical summary of data shown in C. (E) Representative currents from YM201636-enlarged LE/LY isolated from
murine (LPS 6 hr or LPS 0 hr) primary WT alveolar macrophages (AMF), basal or elicited by an application of 10 mM ML2-SA1. (F) Statistical summary of
data shown in E. * indicates p<0.05, ** indicates p<0.01, Student’s t test, unpaired. (G) qPCR data showing levels of TRPML2 expression after 3, 6, and
24 hr LPS treatment compared to untreated (0 hr). * indicates p<0.05, ** indicates p<0.01, one-way ANOVA test followed by Tukey’s post-hoc test.
Figure 4 continued on next page
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secretion of these chemokines. However, it remained unclear whether TRPML2 is directly involved in
these processes and whether activation of TRPML2 channel activity would show increased release.
Here, we present data strongly supporting a direct involvement of TRPML2, as direct stimulation
of TRPML2 with ML2-SA1 leads to an increase in CCL2 secretion from macrophages. Using the spe-
cific TRPML2 agonist and the TRPML2-/- knockout mouse model as control, we demonstrate a posi-
tive relationship between TRPML2 activity and CCL2 secretion. Using the endolysosomal patch-
clamp technique we demonstrate that TRPML2 is present in LE/LY and EE as well as in Rab11+ and
TfR+/Tf+ vesicles (Supplementary file 2). However, early endosomes including RE provide more
favorable activation conditions for TRPML2 than LE/LY due to their less acidic/neutral luminal pH. In
accordance with this, TRPML2 currents elicited with ML2-SA1 in LE/LY isolated from endogenously
expressing BMDMF were smaller than currents in Tf+ vesicles. In addition, no evidence was found
that ML2-SA1 can promote lysosomal exocytosis, while ionomycin or ML-SA1 were able to increase
the release of beta-hexosaminidase as previously reported (Samie et al., 2013). The subcellular dis-
tribution of LAMP1 did also not change during ML2-SA1 treatment and no translocation to the PM
was observed. In contrast, ML2-SA1 application was found to significantly promote Tf trafficking
through the early/recycling endosomal compartment, arguing for a role of TRPML2 in CCL2 release
via the early/recycling endosomal pathway (Figure 5F).
Loss of function mutations in the TRPML2-related channel TRPML1 result in lysosomal storage
and endolysosomal trafficking defects underlying the neurodegenerative disease mucolipidosis type
IV (Bach, 2001; Pryor et al., 2006; Chen et al., 2014). Mechanistically, it was postulated that loss of
TRPML1 impairs lysosomal exocytosis (LaPlante et al., 2006). It was also suggested that TRPML1 is
required for lysosomal pH regulation (Soyombo et al., 2006) and for vesicle fusion
(Venkatachalam et al., 2013) while, very recently, data have been presented, supporting that
TRPML1 may regulate lysosomal fission (Chen et al., 2017a). A further interesting finding has been
presented by Park et al. (2016), suggesting that, in secretory cells, a major role for TRPML1 is to
guard against unintended, pathological fusion of lysosomes with other intracellular organelles, for
example secretory vesicles. TRPML1 has also been attributed to mediate lysosomal trafficking via
Ca2+-dependent motor protein recruitment, its activity favoring retrograde lysosomal movement
(Vergarajauregui et al., 2009; Li et al., 2016).
Like TRPML1, TRPML3 was also suggested to regulate membrane trafficking. In particular, it was
found to regulate trafficking of early endosomes and to affect endocytosis (Kim et al., 2009).
Lelouvier and Puertollano (2011) further presented data showing that TRPML3 is required for
proper calcium homeostasis in the endosomal pathway and that impairment of TRPML3 function
leads to defective endosomal acidification and defective membrane trafficking. Surprisingly, the
authors found increased endosomal fusion after depletion of TRPML3. Recently, Miao et al. (2015)
showed that TRPML3 activation, upon neutralization of lysosomal pH, mediates efflux of Ca2+ ions
from lysosomes, which in turn induces lysosome exocytosis. TRPML3 is normally inactive in highly
acidic lysosomes, in contrast to early/recycling endosomes with more neutral pH, but when the pH in
the lumen of the lysosome is neutralized, TRPML3 becomes activated, releases Ca2+ into the cytosol,
which in turn triggers spontaneous exocytosis of the lysosome and its contents.
TRPML2 has been suggested to play a role in the regulation of the Arf6-associated pathway and,
more specifically, in the trafficking of GPI-APs (Karacsonyi et al., 2007). Arf6 has been implicated in
the regulation of endocytosis as well as endocytic recycling and cytoskeleton remodeling. More
recently, TRPML2 has been found to increase trafficking efficiency of endocytosed viruses
(Rinkenberger and Schoggins, 2018). Furthermore, we are showing here that TRPML2 is, like its rel-
atives TRPML1 and 3, Ca2+ permeable (Figure 2—figure supplement 1C).
Taken together, these findings imply that all three TRPML channels can impact intracellular traf-
ficking processes while the mechanisms how they affect trafficking might differ. While it is likely,
based on the available data, that the effect of TRPML2 knockout/activation on CCL2 trafficking and
release is occurring at the level of EE/RE, it remains to be further established where along this path-
way the effect takes place. Possible scenarios might be: fusion of Golgi vesicles with RE, fission from
Figure 4 continued
DOI: https://doi.org/10.7554/eLife.39720.012
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Figure 5. Effect of ML2-SA1 on chemokine release from primary mouse macrophages. (A) Shown are data obtained from primary WT and TRPML2-/-
mouse bone marrow macrophages (BMDMF) with and without LPS treatment for 4 hr and 8 hr, respectively. The fraction treated with LPS and 10 mM
ML2-SA1 showed significantly increased CCL2 secretion compared to WT controls treated with LPS only. TRPML2-/- cells displayed strongly reduced
CCL2 secretion. Shown are normalized mean values ± SEM of 5 mice each. * indicates p<0.05, Student’s t test, unpaired. (B) Lysosomal exocytosis assay
showing the increase in beta-hexosaminidase release upon stimulation with either ionomycin, ML-SA1, or ML2-SA1 (conc. as indicated) from LPS (6 hr)
Figure 5 continued on next page
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RE, fusion of Golgi vesicles with EE, fission from EE, fusion of EE-derived vesicles with the RE
(Figure 5F).
Functionally, we found that ML2-SA1 promotes migration of untreated macrophages towards
LPS-treated macrophages. This suggests that TRPML2-dependent CCL2 release is enhancing the
inflammatory response by recruiting innate immune cells to the site of inflammation. This is in accor-
dance with the results presented by Sun et al. (2015) who found that macrophage migration is
impaired in vivo in the absence of TRPML2.
Figure 5 continued
stimulated BMDMF. *** indicates p<0.001, one-way ANOVA test followed by Tukey’s post-hoc test. (C) Lysosomal exocytosis assay by flow cytometry
showing the percentage of cells which show an increase in LAMP1 fluorescence on the plasma membrane. Cells were treated with DMSO, calcium
ionophore A23187 (calcimycin), and 30 mM ML2-SA1. (D–E) Recycling endosome assay showing the decrease of Tf mean fluorescence in LPS stimulated
RAW264.7 cells, treated with either DMSO or 30 mM ML2-SA1. Scale bar (identical for all images)=10 mm. Plot shows the normalized Tf intensity (shown
is the average of 3 independent experiments, each). **p<0.01, two-way ANOVA, repeated measures, followed by Bonferroni post-hoc test. (F) Cartoon
showing organelles with functional TRPML2 expression as confirmed by endolysosomal patch-clamp analysis (EE, RE, LE/LY). CCL2 (MCP-1) is
hypothesized to be trafficked and secreted via the EE/RE pathway, based on the observation that ML2-SA1 promotes Tf trafficking in the EE/RE
compartment, while no effect on lysosomal exocytosis was found. No secretory vesicles are reported to exist in macrophages.
DOI: https://doi.org/10.7554/eLife.39720.013
Figure 6. Effect of ML2-SA1 on macrophage migration. (A) Shown are representative images obtained from a modified Boyden chamber experiment.
Images show fixed and crystal violet stained BMDMF after 3 hr migration through a transwell chamber along a chemotactic gradient created by
BMDMF in the lower compartment. Indicated treatments refer to treatment of the cells in the lower compartment. (B) Quantification of migration in the
modified Boyden chamber setup (A) shows a significant increase in migration when LPS pre-treated cells in the lower compartment were subjected to
10 or 30 mM ML2-SA1. Shown are mean values ± SEM of 4 independent experiments. * indicates p<0.05, ** indicates p<0.01, repeated measures, one-
way ANOVA with Greenhouse-Geisser correction, followed by Dunnet post-hoc test.
DOI: https://doi.org/10.7554/eLife.39720.014
The following figure supplements are available for figure 6:
Figure supplement 1. Modified and classical Boyden chamber setup.
DOI: https://doi.org/10.7554/eLife.39720.015
Figure supplement 2. Migration assay without cells in the lower compartment of the classical Boyden chamber.
DOI: https://doi.org/10.7554/eLife.39720.016
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CCL2 is known to be a key chemokine regulating migration and infiltration of monocytes/macro-
phages (Deshmane et al., 2009). Since CCL2 is implicated in the pathogenesis of diseases charac-
terized by infiltrates containing macrophages like psoriasis, rheumatoid arthritis, multiple sclerosis,
and atherosclerosis (Deshmane et al., 2009; Xia and Sui, 2009; Daly and Rollins, 2003), we postu-
late that TRPML2 may be an attractive novel target for the treatment of such innate immunity-
related inflammatory diseases.
Materials and methods
Key resources table
Designation Source or reference Identifiers Additional information
HEK293 DSMZ ACC 305
HEK 293 stable stably
expressing TRPML3-YFP
Grimm et al. (2010);
PMID: 20189104
HEK 293 stable stably
expressing TRPML1-YFP
Chen et al. (2014),
PMID: 25119295
TRPML1 (encoded by
the Mcoln1 gene) KO
mouse; Mcoln1tm1Sasl,
C57BL/6
Venugopal et al. (2007);
PMID: 17924347
MGI ID: 3794204
TRPML2 (encoded by
the Mcoln2 gene) KO
mouse; C57BL/6
Sun et al. (2015);
PMID: 26432893
MGI: 1915529
TRPML3 (encoded by the
Mcoln3 gene)
KO mouse; Mcoln3tm1.
1Hels, FVB/NJ
Jo¨rs et al. (2010);
PMID: 21179200
MGI ID: 5319089
anti-LAMP-1 (1D4B)
(rat monoclonal)
Santa Cruz Cat#A-11006; RRID: AB_2134495 (1:100)
Goat anti-Rat IgG (H + L)
Secondary Antibody,
Alexa Fluor 488
ThermoFisher Cat#sc-19992; RRID: AB_2534074 (1:1000)
mcherry-Transferrin
Receptor 20 (plasmid)
N/A Addgene Plasmid #55144
DsRed-Rab11 (plasmid) Choudhury et al. (2002);
PMID: 12070301
Addgene Plasmid #12679
TRPML1-YFP (plasmid) Grimm et al. (2010),
PMID: 20189104
TRPML2-YFP (plasmid) Grimm et al. (2010),
PMID: 20189104
TRPML3-YFP (plasmid) Grimm et al. (2010),
PMID: 20189104
Quikchange primers for
TRPML2:YFP A422C
this paper forward: CTTCGGTTTTGTTGTTGTG
CTGGTATGATTTATCTGGG
reverse: CCCAGATAAATCATACCAGC
ACAACAACAAAACCGAAG
Quikchange primers for
TRPML2:YFP A424V
this paper forward: CGGTTTTGTGCTTG
TGTTGGTATGATTTATCTGGGTTACAC
reverse: GTGTAACCCAGATAAATCAT
ACCAACACAAGCACAAAACCG
Quikchange primers for
TRPML2:YFP G425A
this paper forward: CGGTTTTGTGCTTGT
GCTGCTATGATTTATCTGGGTTACAC
reverse: GTGTAACCCAGATAAATCA
TAGCAGCACAAGCACAAAACCG
Quikchange primers for
TRPML2:YFP A453S
this paper forward: CTGAACACAGTTTCTG
AGTGTCTGTTTTCTCTGG
reverse: CCAGAGAAAACAGACA
CTCAGAAACTGTGTTCAG
Continued on next page
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Continued
Designation Source or reference Identifiers Additional information
Quikchange primers for
TRPML2:YFP V460I
this paper forward: TGTCTGTTTTCTCTGATCA
ACGGTGATGACATG
reverse: CATGTCATCACCGTTGATC
AGAGAAAACAGACA
Quikchange primers for
TRPML2:YFP I498V
this paper forward: CCTTCATCAGCCTTTTTATATATA
TGGTTCTCAGTCTTTTTATTGC
reverse: GCAATAAAAAGACTGAGAACCA
TATATATAAAAAGGCTGATGAAGG
qPCR Primer for TRPML1
(NM_053177)
www.pga.mgh.
harvard.edu/primerbank
PrimerBankID: 16716462 c2 forward: GCCTTGGGCCAATGGATCA
reverse: CCCTTGGATCAATGTCAAAGGTA
qPCR Primer for TRPML2
(NM_026656)
this paper forward: AATTTGGGGTCACGTCATGC
reverse: AGAATCGAGAGACGCCATCG
qPCR Primer for TRPML3
(NM_134160)
this paper forward: GAGTTACCTGGTGTGGCTGT
reverse: TGCTGGTAGTGCTTAATTGTTTCG
qPCR Primer for HPRT
(NM_013556)
Hruz et al. (2011);
PMID: 21418615
N/A forward: GCTCGAGATGTCATGAAGGAGAT
reverse: AAAGAACTTATAGCCCCCCTTGA
Lipopolysaccharides (LPS)
from Escherichia coli O26:B6
Sigma-Aldrich Cat#L2762
Lipopolysaccharides (LPS)
from Escherichia coli O111:B4
Sigma-Aldrich Cat#L4391
Fura-2, AM, cell
permeant
ThermoFisher Cat#F1201
Mouse M-CSF,
premium grade
Miltenyi Biotech Cat#130-101-703
Transferrin from human
serum, Alexa FluorTM
546-conjugated
TermoFisher Cat# T23364
Transferrin from human
serum, Alexa FluorTM
555-conjugated
Thermo Fisher Cat#T35352
JE/MCP-1/CCL2 from
mouse, recombinant
Sigma-Aldrich Cat# SRP4207
YM201636 Chemdea Cat#CD0181
MLSA-1 Sigma-Aldrich Cat#SML0627
PI(3,5)P2 AG Scientific Cat#P-1123
Wortmannin Sigma-Aldrich Cat#W1628
LatrunculinB Sigma-Aldrich Cat#L5288
Vacuolin Santa Cruz Cat# sc-216045
Calcium ionophore A23187 Sigma-Aldrich Cat#C7522
4-Methylumbelliferyl
N-acetyl-b-D-glucosaminide
Sigma-Aldrich Cat#M2133
RNeasy Plus Mini Kit Qiagen Cat# 74134
RevertAid first strand
cDNA synthesis Kit
ThermoScientific Cat# K1621
CD11b MicroBeads,
human and mouse
Miltenyi Biotech Cat#130-049-601
QuikChange II
Site-Directed
Mutagenesis Kit
Agilent Cat#200523
Mouse/rat CCL2/
JE/MCP-1 Quantikine
ELISA Kit
BioLegend Cat#432707
Origin8 OriginLab
GraphPad Prism GraphPad Software Inc.
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Endolysosomal patch-clamp and calcium imaging experiments
Whole-LE/LY and whole-EE recordings have been described previously in detail (Chen et al., 2017a;
Chen et al., 2017c). In brief, for whole-LE/LY manual patch-clamp recordings, cells were treated
with YM201636 (HEK293 cells: 800 nM o/n; macrophages: 800 nM 1 hr). For whole-EE manual
patch-clamp recordings, cells were treated with a combination of 200 nM wortmannin and 10 nM
latrunculin B (HEK293 cells: 10–15 min). Cells were treated with compounds at 37˚C and 5% CO2.
YM201636 was obtained from Chemdea (CD0181), wortmannin and latrunculin B from Sigma
(W1628 and L5288), and vacuolin from Santa Cruz (sc-216045). Compounds were washed out before
patch-clamp experimentation.
For other organelle patch-clamp recordings, HEK293 cells were transfected with the markers
Rab11-DsRed or TfR-mCherry, respectively, and treated with 1 mM vacuolin o/n. Since macrophages
could not be transfected with standard transfection protocols or by electroporation, cells were
loaded with transferrin-Alexa555 and simultaneously treated with vacuolin for 1 hr to enlarge and
visualize vesicles for patch-clamp.
Isolation-micropipettes were used to open up the plasma membrane, and push the enlarged vesi-
cle of interest out of the cell. Afterwards, electrode-micropipettes were applied to patch-clamp the
isolated vesicles.
Macrophages were used for experiments within 2–10 days after isolation. Mean capacitance val-
ues for Rab11+ vesicles isolated from HEK293 cells was 0.7 ± 0.2 (n = 6), for TfR+ vesicles (n = 3)
1.4 ± 0.3 pF, for EE (n = 10) 0.4 ± 0.1 pF, and for LE/LY (n = 51) 1.0 ± 0.2 pF. For LE/LY isolated from
primary macrophages it was 0.8 ± 0.1 pF (n = 41), for Tf-loaded vesicles 1.3 ± 0.5 pF (n = 8). Currents
were recorded using an EPC-10 patch-clamp amplifier (HEKA, Lambrecht, Germany) and PatchMas-
ter acquisition software (HEKA). Data were digitized at 40 kHz and filtered at 2.8 kHz. Fast and slow
capacitive transients were cancelled by the compensation circuit of the EPC-10 amplifier. Recording
glass pipettes were polished and had a resistance of 4–8 MW. For all experiments, salt-agar bridges
were used to connect the reference Ag-AgCl wire to the bath solution to minimize voltage offsets.
Liquid junction potential was corrected. For the application of the lipids (A.G. Scientific) or small
molecule agonists (ML2-SA1, ML-SA1), cytoplasmic solution was completely exchanged by cyto-
plasmic solution containing agonist. Unless otherwise stated, cytoplasmic solution contained 140
mM K-MSA, 5 mM KOH, 4 mM NaCl, 0.39 mM CaCl2, 1 mM EGTA and 10 mM HEPES (pH was
adjusted with KOH to 7.2). Luminal solution contained 140 mM Na-MSA, 5 mM K-MSA, 2 mM Ca-
MSA 2 mM, 1 mM CaCl2, 10 mM HEPES and 10 mM MES (pH was adjusted with NaOH to 7.2). For
optimal conditions of TRPML1, luminal pH was adjusted to 4.6 and Na-MSA was used in the luminal
solution. For optimal conditions of TRPML2, luminal pH was adjusted to 7.2 and Na-MSA was used
in the luminal solution. For optimal conditions of TRPML3, luminal pH was adjusted to 7.2 and
K-MSA was applied to replace Na-MSA in the luminal solution. In all experiments, 500 ms voltage
ramps from  100 to +100 mV were applied every 5 s, holding potential at 0 mV. The current ampli-
tudes at  100 mV were extracted from individual ramp current recordings. All statistical analysis was
done using Origin8 software.
Calcium imaging experiments were performed using fura-2 as described previously
(Grimm et al., 2012a). Briefly, HEK293 cells were plated onto glass coverslips, grown over night and
transiently transfected with the respected cDNAs using TurboFect transfection reagent (Thermo Sci-
entific). After 24–48 h cells were loaded for 1 hr with the fluorescent indicator fura2-AM (4 mM; Invi-
trogen) in a standard bath solution (SBS) containing (in mM) 138 NaCl, 6 KCl, 2 MgCl2, 2 CaCl2, 10
HEPES, and 5.5 D-glucose (adjusted to pH 7.4 with NaOH). Cells were washed in SBS for 30 min
before measurement. Calcium imaging was performed using a monochromator-based imaging sys-
tem (Polychrome IV mono-chromator, TILL Photonics).
Computational methods
Analysis of electron density map. The electron density maps for the cryo-electron microscopy struc-
tures of hTRPML1 and hTRPML3 in open agonist-bound form (PDB IDs: 5WJ9 and 6AYF, respec-
tively) were downloaded from the Protein Data Bank (PDB; ww.rcsb.org) (Berman et al., 2000) and
visualized in PyMOL (The PyMOL Molecular Graphics System, Version 1.7.4 Schro¨dinger, LLC).
Homology modelling of TRPML2. The amino acid sequence of hTRPML2 was retrieved from UniProt
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(The UniProt Consortium, 2017); Accession number: Q8IZK6-1) and a Blast (Altschul et al., 1990)
search using BLOSUM62 matrix was performed against the PDB to find the closest homologues.
Subsequently, sequence alignment of hTRPML2 to the top scored template, hTRPML3 (Sequence
identity 59%), was conducted in MOE2012.10 (Molecular Operating Environment (MOE), 2016.08;
Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A
2R7, 2016) and the alignment file was used to generate the homology model using MODELLER 9.11
(Webb and Sali, 2014). Ligand-bound homology models of hTRPML2 were finally built using the
agonist-bound structure of hTRPML3 (PDB ID: 6AYF) and ranked according to their DOPE score
(Shen and Sali, 2006). Molecular docking to hTRPML1 and  2. The ligands were prepared for dock-
ing using the LigPrep tool as implemented in Schro¨dinger’s software (Schro¨dinger Release 2017–1:
LigPrep, Schro¨dinger, LLC, New York, NY, 2017), where the two stereoisomers of ML2-SA1 were
generated and energy minimized using the OPLS force field. Conformers of the prepared ligands
were calculated with ConfGen using the default settings and allowing minimization of the output
conformations.
Protein preparation. The cryo-electron microscopy structure of the open conformation of
hTRPML1 in complex with ML-SA1 (PDB ID: 5WJ9) and the generated hTRPML2 homology model
were prepared with Schro¨dinger’s Protein Preparation Wizard (Schro¨dinger Release 2017–1: Schro¨-
dinger Suite 2017–1 Protein Preparation Wizard; Epik, Schro¨dinger, LLC, New York, NY, 2016;
Impact, Schro¨dinger, LLC, New York, NY, 2016; Prime, Schro¨dinger, LLC, New York, NY, 2017):
Hydrogen atoms were added and the H-bond network was subsequently optimized. The protonation
states at pH 7.0 were predicted using the PROPKA tool in Schro¨dinger. The structures were finally
subjected to a restrained energy minimization step using the OPLS2005 force field (RMSD of the
atom displacement for terminating the minimization was 0.3 A˚).
The receptor grid preparation for the docking procedure was carried out by assigning the agonist
as the centroid of the grid box. The generated ligand conformers were docked into the proteins
using Glide (Small-Molecule Drug Discovery Suite 2017–1: Glide, Schro¨dinger, LLC, New York, NY,
2017) in the Standard Precision mode. A total of 100 poses per ligand conformer were included in
the post-docking minimization step and a maximum of 20 docking clusters were output for each
ligand. Redocking of the ligand ML-SA1 into the hTRPML1 pocket gave a docking pose with root
mean square deviation of 1.22 A˚ for the top-ranked solution (Figure 3—figure supplement 1A).
Cell culture of primary macrophages isolated from knockout and WT
mice
For preparation of primary alveolar macrophages (AMF), mice were deeply anesthetized and eutha-
nized by exsanguination. Afterwards, the trachea was carefully exposed and cannulated by inserting
a 20 gauge catheter (B. Braun, cat. no. 4252110B). AMF were harvested by eight consecutive lung
lavages with 1 ml of DPBS each. After a centrifugation step, cells were immediately collected and
cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% antibiotics. AMF
were directly seeded onto 12 mm glass cover slips and used for experiments within 5 days after
preparation. Bone marrow-derived macrophages (BMDMF) were isolated from femur and tibias of
mice. Thus, bones were isolated and bone marrow was flushed with 10 ml PBS using a sterile 25
gauge needle. Cells were obtained by centrifugation, resuspended and subsequently cultured in 10
cm petri dishes in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin and 40 ng/mL murine M-CSF (Miltenyi Biotech). Cells were incubated for 5 days,
before they were plated onto poly-L-lysine coated cover slips for experiments. All cells were main-
tained at 37˚C in 5% CO2 atmosphere. If necessary, cells were stimulated with 1 mg/mL LPS (Escheri-
chia coli O26:B6, Sigma, L2762) prior to experiments for different time periods as stated in the text.
Animals were used under approved animal protocols and University of Munich (LMU) Institutional
Animal Care Guidelines.
Measurement of CCL2 content in bmdm’ culture supernatants by
ELISA
Cell culture supernatants from WT or TRPML2-/- BMDMF were collected at 4 hr or 8 hr following
LPS treatment in the presence or absence of TRPML2 agonist (ML2-SA1), and CCL2 was measured
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using an ELISA kit (BioLegend, 432707), per the manufacturer’s instructions. Cell culture superna-
tants were diluted ten times for the assay, and 50 mL diluted supernatant was assessed.
Transferrin trafficking assay
RAW264.7 cells were seeded overnight with 0.1 mg/mL of lipopolysaccharide (LPS) (L4391, Sigma).
Then, cells were loaded for 20 min at 37˚C with transferrin from human serum, Alexa Fluor 546-con-
jugated (T23364, ThermoFisher) at the concentration of 50 mg/mL in complete medium (DMEM 10%
FBS). The analysis of recycling kinetics was performed by chasing for 5, 10, 15 and 20 min in com-
plete media plus 50 mg/mL of unconjugated transferrin (T0665, Sigma) in the presence of either
DMSO or ML2-SA1 (30 mM). Before fixation with 4% paraformaldehyde (PFA), non-internalized trans-
ferrin was acid-stripped (150 mM NaCl, 0.5% acetic acid in H2O) for 30 s. Images were acquired
using a Zeiss LSM 800 with 63x magnification.
Lysosomal exocytosis assay (FACS)
RAW264.7 cells were seeded overnight with 0.1 mg/mL of lipopolysaccharide (LPS) (L4391, Sigma).
Then, cells were treated with DMSO, calcium ionophore A23187 (C7522, Sigma) or ML2-SA1 for 3
hr. After 3 h cells were collected and stained with LAMP1 antibody (SC-19992, Santa Cruz) in PBS
(1% BSA) during agitation for 20 min (4˚C). Cells were then collected by centrifugation and resus-
pended in PBS (1% BSA) with goat anti-rat, Alexa488 (A-11006 ThermoFisher) during agitation for 1
hr (4˚C). Finally, cells were washed in PBS and left on ice until FACS analysis. Cells were loaded into
the FACS machine using a nozzle of 100 mm and the LAMP1 fluorescence intensity was measured
using a 488 nm excitation laser and a FITCH (530/30 nm) emission filter. The threshold was set using
DMSO-treated samples, and 1000 events were counted for each condition.
Lysosomal exocytosis assay (Hexosaminidase)
For measurement of lysosomal hexosaminidase enzyme release, bone marrow macrophages were
treated with ML2-SA1, ML-SA1 or DMSO in serum-free RPMI medium, concentrations and durations
as indicated. Ionomycin was used as control. After treatment, supernatants were collected, centri-
fuged and incubated with natrium citrate buffer (pH 4.5) and 4-Methylumbelliferyl N-acetyl-b-D-glu-
cosaminide (M1233, Sigma, 1 mM final concentration) for 1.5 hr. Cells were lysed with Triton-X
buffer and lysates were processed in parallel. The reaction was stopped by adding glycin buffer to
the samples and the turnover of hexosaminidase substrate was detected as fluorescence (Exitation:
365 nm; Emission: 450 nm) using a plate reader (Spectramax ID3, Molecular Devices). The increase
in substrate turnover was analyzed as fluorescence increase in supernatants relative to lysates.
Site-directed mutagenesis
Generation of point mutant isoforms of hTRPML2 (encoded by the MCOLN2 gene) was performed
as described previously (Grimm et al., 2010) using the QuikChange protocol. The following primers
were used to generate hTRPML2 mutant isoforms: A422C forward primer: CTTCGGTTTTGTTGTTG
TGCTGGTATGATTTATCTGGG; A422C reverse primer: CCCAGATAAATCATACCAGCACAACAA-
CAAAACCGAAG; A424V forward primer: CGGTTTTGTGCTTGTGTTGGTATGATTTATCTGGGTTA-
CAC; A424V reverse primer: GTGTAACCCAGATAAATCATACCAACACAAGCACAAAACCG;
G425A forward primer: CGGTTTTGTGCTTGTGCTGCTATGATTTATCTGGGTTACAC; G425A
reverse primer: GTGTAACCCAGATAAATCATAGCAGCACAAGCACAAAACCG; A453S forward
primer: CTGAACACAGTTTCTGAGTGTCTGTTTTCTCTGG; A453S reverse primer: CCAGAGAAAA-
CAGACACTCAGAAACTGTGTTCAG; V460I forward primer: TGTCTGTTTTCTCTGATCAACGGTGA
TGACATG; V460I reverse primer: CATGTCATCACCGTTGATCAGAGAAAACAGACA; I498V forward
primer: CCTTCATCAGCCTTTTTATATATATGGTTCTCAGTCTTTTTATTGC; I498V reverse primer:
GCAATAAAAAGACTGAGAACCATATATATAAAAAGGCTGATGAAGG.
Macrophage migration experiments
ML2-SA1 effects on macrophage migration were assessed by a modified Boyden chamber setup
(Figure 6—figure supplement 2). In the modified Boyden chamber setup, BMDMF were plated
onto poly-L-lysine coated cover slips in a twenty-four well plate (lower compartment) in the presence
or absence of 1 mg/ml LPS for 6 hr. After 6 hr, media was replaced with media containing 10 or 30
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mM ML2-SA1 or DMSO. 1  105 BMDMF were placed on top of the transwell chamber (Corning) in
media without any compound. Transwell chambers were placed into the twenty-four well plate and
incubated for 3 hr at 37˚C in 5% CO2 atmosphere. In the classical Boyden chamber approach a
twenty-four well plate was filled with media containing either DMSO, 1 mg/ml LPS and DMSO, 1 mg/
ml LPS and 30 mM ML2-SA1, or 10 ng/ml CCL2. Transwell chambers were equally prepared and incu-
bated. Migrated cells were fixed and stained with crystal violet/methanol. The top of the transwell
chamber was cleaned an images were taken. Cell covered area was determined with ImageJ (NIH,
Bethesda, MD).
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